Which company is the manufacturer of ibrutinib?

Ibrutinib/ibrutinib (Ibrutinib) is developed and produced by Janssen Pharmaceuticals. Janssen Pharmaceuticals is the pharmaceutical division of Johnson & Johnson. As an oral targeted drug, ibrutinib inhibits Bruton's tyrosine kinase (BTK) and is suitable for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia (WM), and mantle cell lymphoma (MCL) who have received at least one treatment.

The active ingredient in ibrutinibibrutinib can fight against cancerous B lymphocytes, which are a type of white blood cell. It does this by blocking an enzyme called Bruton's tyrosine kinase (BTK; also known as B lymphocyte kinase), which promotes the survival of B lymphocytes and their migration to healthy organs. By blocking BTK, ibrutinib reduces B lymphocyte survival and migration, thereby delaying cancer progression.

Ibrutinib, as a targeted drug, has made a breakthrough in the treatment of chronic lymphocytic leukemia and other related diseases. Its R&D and production benefit from Janssen Pharmaceutical Company's rich experience and strong technical strength in the pharmaceutical field. The company is committed to improving patients' quality of life through innovative drug research and development and providing efficient and safe treatment options to patients.

The advent of ibrutinib has brought new hope to patients with CLL, SLL, WM and MCL. Due to its accurate targeting and improvement in patients' quality of life, ibrutinib has not only been widely used in clinical practice, but has also had a profound impact in the fields of scientific research and new drug development, opening up new possibilities for conquering more types of blood cancers.